Indian vaccine company Bharat Biotech is all set to launch its intranasal Covid vaccine iNCOVACC on January 26. In her interactions with students at the India International Science Festival in Bhopal, MD Krishna Ella mentioned that the expected launch date of the indigenously produced Lumpi-ProVacInd vaccine for the lumpy skin disease in cattle is next month.
Ella said, “Our nasal vaccine will be officially launched on January 26, on Republic Day,” participating in the ‘Face-to-Face with New Frontiers in Science’ segment of the IISF, organised at the Maulana Azad National Institute of Technology (MANIT).
For purchase by the government, the intranasal vaccine would cost Rs 325 for each shot, while it would cost Rs 800 per shot for private immunisation facilities, according to a December announcement by Bharat Biotech.
The Central Drugs Standard Control Organization approved the nasal vaccination in December. Later that month, the National Technical Advisory Group on Immunization in India suggested adding it to the list of “precautionary doses” that adults can take as boosters.
Nine locations around the nation hosted the 875 participants in the nasal clinical trials. The recombinant adenoviral vector construct for the vaccine was created and produced by Washington University in St. Louis, and its efficacy was assessed in preclinical investigations.